CICC Initiates Coverage of Pfizer Inc. (PFE) With an Outperform Rating [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
In a separate development, Pfizer Inc. (NYSE:PFE) announced on March 23 topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405. The company stated that the vaccine candidate PF-07307405 (LB6V) exhibited over 70% efficacy in preventing Lyme disease in individuals aged five years and above, adding that the investigational vaccine candidate was well-tolerated with no safety concerns identified at the time of analysis. Pfizer Inc. (NYSE:PFE) further stated that the overall results bolster confidence in the vaccine candidate and that the company is planning submissions to regulatory authorities. UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target Annaliesa Anderson, Ph.D., Senior Vice President and Chief Vaccines Officer, Pfizer Inc. (NYSE:PFE), stated that no vaccine is currently available for Lyme disease, and the efficacy shown in the VAL
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says [Yahoo! Finance Canada]Yahoo! Finance Canada
- Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says [Yahoo! Finance]Yahoo! Finance
- After her cancer misdiagnosis, Lucy Liu advocates for early screening [USA TODAY]USA TODAY
- Pfizer (PFE) had its "underperform" rating reaffirmed by Royal Bank Of Canada. They now have a $25.00 price target on the stock.MarketBeat
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 2/3/26 - Beat
PFE
Sec Filings
- 4/17/26 - Form 4
- 4/16/26 - Form 4
- 4/10/26 - Form 3
- PFE's page on the SEC website